{"filings":[{"id":91102,"accession_number":"0001104659-26-040260","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Northwest Biotherapeutics completes acquisition of UK CDMO Advent BioServices for ~$1.9M plus ~$8.3M payables","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration: ~$1.9M (£1.4M) purchase price plus ~$8.3M in accounts payable to Advent; unpaid balance accrues 7.5% interest.","Payment in installments over 2 years starting 3 months after close, with potential acceleration upon DCVax-L regulatory approval.","Related-party transaction: CEO Linda Powers controls seller; approved per company policies.","Company retired 12M shares and cancelled 5.5M stock options previously issued to Advent.","SEC granted waiver from providing Advent financial statements and pro forma info under Regulation S-X."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101015,"accession_number":"0001104659-26-004146","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NWBO settles 2020 option litigation; insurer pays $2.25M, 17% options cancelled","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement agreement entered Dec 12, 2025 for litigation over 2020 option awards.","Insurance carriers to pay $2.25 million to the company.","17% of challenged 2020 options will be cancelled.","Plaintiff may seek up to $3.5M in attorney fees, paid separately by insurers.","Court approval hearing set for 1:30 pm ET on March 16, 2026 in Delaware."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101014,"accession_number":"0001104659-26-000243","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.07","5.03","9.01"],"status":"ready","headline":"NWBO shareholders OK share increase to 2.6B, elect Pat Sarma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 1.7B to 2.6B; 89.65% of votes cast in favor.","Over 77% of total voting power represented at annual meeting; quorum present.","Pat Sarma elected as Class II director for three-year term with 81.1% of votes for.","Ratified Cherry Bekaert LLP as independent auditor for FY2025 (93.76% for).","Advisory vote on executive compensation approved with 77.23% of votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117356,"accession_number":"0001104659-25-114627","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"NWBO enters $5M convertible note with Yorkville for Sawston facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Promissory note of $5M with YA II PN, Ltd. (Yorkville) for 12 months, no payments due until maturity.","Note carries 5% original issue discount, no interest, and convertible at a small discount to market price.","Monthly conversion limited to ~1/5 of note amount unless conversion price above $0.29.","Proceeds to fund construction/equipment for first Grade C manufacturing suite at Sawston, UK, plus operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117355,"accession_number":"0001104659-25-104812","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"NW Biotherapeutics enters $5.5M loan agreement with Streeterville Capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan amount $5,505,000; maturity 22 months; interest 8% p.a.; 10% original issue discount.","No payments for first 8 months; 14 equal monthly installments start June 2026 at 110% pro rata principal plus interest.","Prepayment allowed with 10% charge; funds used for ongoing business operations.","Loan includes customary default provisions and potential acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117354,"accession_number":"0001104659-25-104427","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"NWBO closes Advent BioServices acquisition; pays £1.4M + AP over 2 years; 19M securities revert","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Advent BioServices closed; Advent becomes wholly owned subsidiary.","No new shares issued; 13.5M shares and 5.5M options previously issued to Advent revert to NWBO.","Consideration: £1.4 million plus net accounts payable, paid in installments over two years starting 90 days post-closing.","Installment payments may accelerate upon regulatory approval of DCVax-L; NWBO receives fixed assets, cryostorage, and IP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117353,"accession_number":"0001104659-25-102049","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NWBO files new Form S-3 shelf registration to replace expiring registration on Oct 25, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed new S-3 shelf registration on October 23, 2025, effective for three years.","Existing shelf registration expires on October 25, 2025, necessitating replacement filing.","Action taken to maintain continuous ability to offer securities via shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117352,"accession_number":"0001104659-25-099196","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Northwest Biotherapeutics settles shareholder litigation over 2020 options; insurers to pay $2.25M","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement resolves Delaware Chancery litigation over 2020 option awards to management and directors.","17% of challenged options will be cancelled; company's insurers to pay $2.25 million to the company.","Definitive settlement documentation due within 30 days; plaintiff's amended complaint covered by deal.","Plaintiff intends to seek attorneys' fees and expenses, to be paid separately by insurers, subject to court approval.","Cash payment from insurers cannot be used for fee award; both settlement and fee require court approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186526,"accession_number":"0001104659-24-131723","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Northwest Biotherapeutics announces $5M convertible note and $50M standby equity facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered $5M convertible promissory note with Yorkville, 13-month term, 7% original issue discount, no interest.","Conversion at small discount to market price; limited to 1/6 of note per month unless conversion price above $0.315.","Standby equity subscription agreement allows company to require Yorkville to buy up to $50M of common shares after note repaid/converted.","Standby facility has 24-month term; no obligation to draw; company can cancel anytime after note repaid/converted.","Proceeds for general corporate purposes; Joseph Gunnar & Co. acted as exclusive placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186525,"accession_number":"0001104659-24-113553","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Northwest Biotherapeutics enters $5M convertible note with 11% interest, 24-month maturity","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Company entered $5,000,000 convertible note with an unrelated shareholder on Oct 31, 2024.","Note matures in 24 months with no payments due until maturity; interest at 11% per annum.","Holder can convert into common stock at $0.30/share or non-dilutive financial instrument priced at $50,000.","Proceeds will be used for ongoing business operations; customary default provisions apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203103,"accession_number":"0001104659-24-085198","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"NW Bio investigates social media rumors; MHRA MAA review continues","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Company probing rumors linked to parties in federal NY lawsuit; coinciding with stock market developments.","Plans to pursue appropriate action against rumor sources; shareholders asked to report information.","MHRA review of Marketing Authorization Application in UK ongoing; inspections scheduled in US and UK.","CEO Linda Powers signed the disclosure; no financial guidance or earnings data provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203102,"accession_number":"0001104659-24-077718","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NWBO annual meeting re-elects directors, ratifies auditor and option awards, approves exec comp","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected Dr. Alton L. Boynton (94.04% for) and Ambassador J. Cofer Black (93.01% for) as Class I directors for three-year terms.","Ratified Cherry Bekaert LLP as independent auditor for FY2024 with 92.73% of votes cast in favor.","Ratified 2020 option awards to named executive officers (88.13% for) and non-executive directors (88.05% for).","Advisory approval of 2023 executive compensation received 87.37% of votes cast in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219401,"accession_number":"0001104659-24-068314","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Northwest Biotherapeutics sells 8.125M shares at $0.40 to SIO Capital for $3.25M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SPA signed June 4, 2024; closing expected June 5, 2024.","Gross proceeds of $3,250,000 from sale of 8,125,000 shares of common stock.","Proceeds to be used for ongoing business operations.","SIO Capital Management LLC is the purchaser; Joseph Gunnar & Co. acted as placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219400,"accession_number":"0001104659-24-056424","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Northwest Biotherapeutics enters $11M loan agreement with Streeterville Capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan principal of $11,005,000; maturity 22 months; repayments begin Dec 26, 2024.","14 equal monthly installments at 110% of pro rata plus accrued interest (8% per annum).","10% original issue discount; prepayment allowed with 10% charge.","Proceeds fund business ops, construction of first grade C lab in Sawston UK, long lead-time equipment, Flaskworks prep."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}